FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**BENEFICIAL OWNERSHIP** 

Check this box if no longer subject to	STATEMENT OF CHANGES IN
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Clark Eliana						2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [ NTLA ]											icable) or	ng Per	rson(s) to Is	wner		
(Last) (First) (Middle) C/O INTELLIA THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/20/2023										^ below	Officer (give title below)  EVP, Chief Te		Other (s below) cal Office			
		SUITE 130			4. If <i>i</i>	Amer	ndme	nt, Date	of Orig	inal Fi	iled	(Month/D	ay/Yea	r)	6. I Lin		Joint/Group	p Filin	g (Check A	pplicable		
(Street) CAMBRIDGE MA 02139																X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)					_	Rule 10b5-1(c) Transaction Indication																
						X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
''' ''' '				2. Transa Date (Month/D		y/Year) Ex		med on Date, Day/Yea	Cod	Transaction Code (Instr.				ies Acquired (A) or Of (D) (Instr. 3, 4 ar		Benefic Owned	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
		Code V Amount (A) or (D) Price (Instr. 3 and 4) (Instr. 3)									(Instr. 4)											
Common Stock				06/20	06/20/2023				N	1		5,000	0	A \$12.		27 50	50,146		D			
Common	ommon Stock			06/20	/2023				S	1)		5,000	0 D		\$45	45,146			D			
		Ta	able II -	Deriva (e.g., p												y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transac Code (li 8)		of Deri Sec Acq (A) ( Disp of (I	oosed D) tr. 3, 4	6. Date Expira (Month	tion D	ate	ble and	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ect (Instr. 4)		
					Code	v	(A)	(D)	Date Exerci	sable		epiration ate	Title		Amount or Number of Shares							
Stock Option (right to	\$12.27	06/20/2023			M			5,000	(2)		02	2/02/2030	Comm		5,000	\$0.00	57,750		D			

## **Explanation of Responses:**

- 1. The reported sale of 5,000 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- 2. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 64,062 shares as of June 20, 2023.

## Remarks:

James Basta, attorney-in-fact 06/22/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.